Of the 6,000 patients known to have suffered an allergic-like event after the first prescription – such as hives, wheezing or anaphylaxis – 48 percent actually received a second prescription, but only two percent of those had another allergic-like event. Previous medical research, involving smaller case study groups, had placed the figure for recurring allergic-like events at 60 percent. "Penicillin allergy is a significant problem in patient care because it is common and, in rare cases, can be life-threatening," said senior researcher Brian L. Strom, MD, MPH, Professor of public health and preventive medicine, Chair of Penn's Department of Biostatistics and Epidemiology, and Director of Penn's Center for Clinical Epidemiology and Biostatistics (CCEB).
The reasons for the unexpectedly frequent rate of re-prescription remain unclear, but anecdotal evidence suggests that patients often do not know if they really have a penicillin allergy. Current testing – which uses a skin-test reaction and is unavailable to family physicians – remains imperfect for determining true penicillin allergy due to a lack of commercial availability of some of the most useful testing materials. Researchers also calculated, from the records of two million patients who received at least two prescriptions for penicillin, that the risk of having a second allergic-like event was approximately 11-times greater for those who suffered an allergic-like event after the previous treatment – even if, overall, there were far fewer secondary events than expected.
"As one of the cheapest and most effective antibiotics available, it is essential for clinicians to know just how common allergic-like reactions are and when really to avoid re-prescription of penicillin," said Principal Investigator Andrea J. Apter, MD, MSc, Associate Professor of Medicine and allergist/immunologist in Penn's Pulmonary, Allergy and Critical Care Division, and Associate Scholar in the CCEB.
Researchers caution that the rates of second allergic-like events may have been artificially depressed if patients with the most severe allergic-like events did not receive further prescriptions. Nevertheless, this study suggests that there are some patients labeled as penicillin-allergic who can safely receive that antibiotic in time of need and when the alternatives are not as effective. More research is needed to understand how to identify these patients in advance.
Funding for the study was provided through research grants from the Agency for Healthcare Research and Quality Centers for Education and Research on Therapeutics and the National Heart, Lung and Blood Institute.
Editor's Note:
You may also find this news release on-line at www.uphs.upenn.edu/news
PENN Medicine is a $2.2 billion enterprise dedicated to the related missions of medical education, biomedical research, and high-quality patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System (created in 1993 as the nation's first integrated academic health system). Penn's School of Medicine is ranked #2 in the nation for receipt of NIH research funds; and ranked #4 in the nation in U.S. News & World Report's most recent ranking of top research-oriented medical schools. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.
Penn Health System consists of four hospitals (including its flagship Hospital of the University of Pennsylvania, consistently rated one of the nation's "Honor Roll" hospitals by U.S. News & World Report), a faculty practice plan, a primary-care provider network, three multispecialty satellite facilities, and home health care and hospice.
Journal
Journal of Allergy and Clinical Immunology